Pharmacological Treatment of Acute Vertigo in Women
For acute vertigo, offer a limited course (maximum 3 days) of vestibular suppressants such as antihistamines (dimenhydrinate), benzodiazepines, or calcium channel blockers for immediate symptom control, then transition rapidly to disease-specific therapy based on the underlying diagnosis. 1
Immediate Vestibular Suppression
For acute symptomatic relief of severe vertigo with nausea and vomiting:
- Antihistamines (e.g., dimenhydrinate, meclizine)
- Benzodiazepines (e.g., diazepam, lorazepam)
- Calcium channel blockers 2
Critical caveat: Limit vestibular suppressants to maximum 3 days to avoid delaying central compensation and prolonging recovery 3. These medications treat symptoms only, not the underlying pathology.
Disease-Specific Pharmacotherapy
Vestibular Neuritis
Oral corticosteroids are the primary disease-modifying treatment:
- Improves recovery of peripheral vestibular function 4, 5
- Should be initiated early in the acute phase
- After initial symptom control with suppressants, discontinue antivertiginous agents and allow natural compensation to occur
Ménière's Disease
The 2020 AAO-HNS guideline provides a stepwise approach 1:
Initial oral therapy:
- Betahistine at higher dosages (insufficient evidence for 16 mg TID or 48 mg TID; higher doses recommended based on animal studies showing increased cochlear blood flow) 4
- Diuretics as first-line oral options 2
- Limited course of vestibular suppressants for acute attacks 1
Escalation for uncontrolled symptoms:
- Intratympanic steroids may be offered for active disease 1
- Intratympanic gentamicin should be offered for active disease not responsive to non-ablative therapy 1
The guideline explicitly states clinicians should not prescribe positive pressure therapy 1.
Vestibular Migraine
Treatment parallels migraine without aura 4, 6:
Acute treatment:
- Do not use triptans for isolated vertigo/dizziness episodes 7
- Standard antiemetics and vestibular suppressants (limited duration)
Prophylactic therapy (overlapping options with persistent postural-perceptual dizziness):
- Beta-blockers (e.g., metoprolol) - proven approach 6, 7
- Tricyclic antidepressants 2
- Selective serotonin reuptake inhibitors (SSRIs) 2
- Serotonin-norepinephrine reuptake inhibitors (SNRIs) 2
- Calcium channel blockers (flunarizine has one RCT) 4
- Antiepileptic drugs (topiramate) 6, 7
Emerging evidence suggests CGRP antagonists and botulinum toxin A show promise but require further validation 7, 8.
Key Clinical Pitfalls
Prolonged vestibular suppressant use: Beyond 3 days delays central compensation and worsens long-term outcomes 3
Misdiagnosis between Ménière's and vestibular migraine: Serial audiometry is essential—Ménière's requires documented low-to-mid frequency sensorineural hearing loss, while vestibular migraine does not 1, 9
Inadequate betahistine dosing: Lower doses (16-48 mg TID) lack sufficient evidence; higher dosages are recommended for Ménière's disease 4
Using triptans for isolated vestibular migraine vertigo: Reserve triptans for episodes with concurrent headache 7
Treatment Algorithm Summary
- Acute phase (days 1-3): Vestibular suppressants for severe symptoms
- Diagnostic clarification: Audiometry, history of migraine features, duration/character of attacks
- Disease-specific therapy:
- Vestibular neuritis → Corticosteroids
- Ménière's → Betahistine/diuretics → Intratympanic steroids → Intratympanic gentamicin
- Vestibular migraine → Migraine prophylaxis (beta-blockers, antidepressants, antiepileptics)
- Vestibular rehabilitation: Essential for all conditions after acute phase, particularly for failed medical therapy 1